C3orf14 has been shown to be differentially methylated in cervical and prostate cancer [18, 19] while CDR2L and SCARF1 have been proposed to mediate immune response in ovarian and liver cancer, respectively [20–22]. This evidence concerns the gene CEP15 and prostate cancer.